VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q67225105 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241020233159.0
008 241020nneanz||abbn n and d
035 ‎‡a (WKP)Q67225105‏
024 ‎‡a 0000-0001-5519-981X‏ ‎‡2 orcid‏
035 ‎‡a (OCoLC)Q67225105‏
100 0 ‎‡a Andrew H Evans‏ ‎‡9 es‏ ‎‡9 ast‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a অ্যান্ড্রু এইচ ইভান্স‏ ‎‡9 bn‏
400 0 ‎‡a Andrew H Evans‏ ‎‡c researcher‏ ‎‡9 en‏
400 0 ‎‡a Andrew H Evans‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
670 ‎‡a Author's [123I] FP-CIT spect study in vascular parkinsonism and Parkinson's disease‏
670 ‎‡a Author's A young woman with slowly-progressive generalized dystonia‏
670 ‎‡a Author's Automated assessment of bradykinesia and dyskinesia in Parkinson's disease.‏
670 ‎‡a Author's Brief Psychiatric Screening Questionnaire in Parkinson's Disease‏
670 ‎‡a Author's Clinical spectrum of impulse control disorders in Parkinson's disease‏
670 ‎‡a Author's Compulsive drug use linked to sensitized ventral striatal dopamine transmission‏
670 ‎‡a Author's Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry?‏
670 ‎‡a Author's Compulsive use of dopaminergic drug therapy in Parkinson's disease: reward and anti-reward‏
670 ‎‡a Author's Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges‏
670 ‎‡a Author's Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours.‏
670 ‎‡a Author's Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson's disease?‏
670 ‎‡a Author's Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management‏
670 ‎‡a Author's Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease‏
670 ‎‡a Author's Dopamine dysregulation syndrome in Parkinson's disease‏
670 ‎‡a Author's Dyskinetic patients show rebound worsening of affect after an acute L-dopa challenge.‏
670 ‎‡a Author's Establishing apomorphine treatment in Thailand: Understanding the challenges and opportunities of Parkinson's disease management in developing countries‏
670 ‎‡a Author's Evaluation of Nonmotor Symptoms in Diagnosis of Parkinsonism and Tremor‏
670 ‎‡a Author's Excessive hoarding in Parkinson's disease‏
670 ‎‡a Author's Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations‏
670 ‎‡a Author's Feasibility of Smartphone-Based Testing of Interference in Parkinson’s Disease‏
670 ‎‡a Author's Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.‏
670 ‎‡a Author's Impulse control and related disorders in Parkinson's disease: review‏
670 ‎‡a Author's Impulsive and compulsive behaviors in Parkinson's disease.‏
670 ‎‡a Author's Impulsive-compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy‏
670 ‎‡a Author's Integrating Patient Concerns into Parkinson's Disease Management‏
670 ‎‡a Author's Is punding a stereotypy?‏
670 ‎‡a Author's L-Dopa-responsive Parkinson's syndrome in association with phenylketonuria: In vivo dopamine transporter and D2 receptor findings‏
670 ‎‡a Author's Management of Advanced Therapies in Parkinson's Disease Patients in Times of Humanitarian Crisis: The COVID-19 Experience‏
670 ‎‡a Author's Motor inhibition in patients with Gilles de la Tourette syndrome: functional activation patterns as revealed by EEG coherence.‏
670 ‎‡a Author's Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study‏
670 ‎‡a Author's Neuronal intranuclear inclusion disease: report on a case originally diagnosed as dopa-responsive dystonia with Lewy bodies‏
670 ‎‡a Author's Objective Measurement and Characterization of Sleep Benefit in Parkinson's Disease‏
670 ‎‡a Author's Pain and dyskinesia in Parkinson's disease may share common pathophysiological mechanisms - An fMRI study‏
670 ‎‡a Author's Pain sensitivity in Parkinson's disease: Systematic review and meta-analysis‏
670 ‎‡a Author's Parkinson disease: A systemic review of pain sensitivities and its association with clinical pain and response to dopaminergic stimulation‏
670 ‎‡a Author's Parkinsonism due to Kernohan notch: clinical, structural, and functional imaging correlates.‏
670 ‎‡a Author's Parkinson's disease and pain-Nondopaminergic mechanisms are likely to be important too‏
670 ‎‡a Author's Parkinson's disease in the Western Pacific Region‏
670 ‎‡a Author's Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series‏
670 ‎‡a Author's Postural instability, frontotemporal dementia, and ophthalmoplegia: clinicopathological case‏
670 ‎‡a Author's Practical approaches to commencing device-assisted therapies for Parkinson's disease in Australia.‏
670 ‎‡a Author's Progressive parkinsonism, oculomotor abnormalities and autonomic dysfunction: clinicopathological case.‏
670 ‎‡a Author's Punding and dyskinesias‏
670 ‎‡a Author's Punding in Parkinson's disease‏
670 ‎‡a Author's Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome‏
670 ‎‡a Author's Quantifying the impact of dyskinesias in PD: the PDYS-26: a patient-based outcome measure‏
670 ‎‡a Author's Reckless generosity in Parkinson's disease‏
670 ‎‡a Author's Recognition of a dopamine replacement therapy dependence syndrome in Parkinson's disease: a pilot study‏
670 ‎‡a Author's Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations‏
670 ‎‡a Author's Sleep disturbance and impulsive-compulsive behaviours in Parkinson's disease‏
670 ‎‡a Author's Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial‏
670 ‎‡a Author's Subjective perception of sleep benefit in Parkinson's disease: Valid or irrelevant?‏
670 ‎‡a Author's The efficacy of apomorphine - A non-motor perspective‏
670 ‎‡a Author's The use of a color coded probability scale to interpret smell tests in suspected parkinsonism‏
670 ‎‡a Author's Treatment advances in Parkinson disease: Same script different cast?‏
670 ‎‡a Author's Validation of a Smartphone Application Measuring Motor Function in Parkinson's Disease‏
670 ‎‡a Author's Vasogenic oedema with no mass lesion‏
909 ‎‡a (orcid) 000000015519981x‏ ‎‡9 1‏
919 ‎‡a parkinsonsdiseaseandpainnondopaminergicmechanismsarelikelytobeimportanttoo‏ ‎‡A Parkinson's disease and pain-Nondopaminergic mechanisms are likely to be important too‏ ‎‡9 1‏
919 ‎‡a parkinsonsdiseaseinthewesternpacificregion‏ ‎‡A Parkinson's disease in the Western Pacific Region‏ ‎‡9 1‏
919 ‎‡a pathologicalgamblinginparkinsonsdiseaseriskfactorsanddifferencesfromdopaminedysregulationananalysisofpublishedcaseseries‏ ‎‡A Pathological gambling in Parkinson's disease: risk factors and differences from dopamine dysregulation. An analysis of published case series‏ ‎‡9 1‏
919 ‎‡a posturalinstabilityfrontotemporaldementiaandophthalmoplegiaclinicopathologicalcase‏ ‎‡A Postural instability, frontotemporal dementia, and ophthalmoplegia: clinicopathological case‏ ‎‡9 1‏
919 ‎‡a practicalapproachestocommencingdeviceassistedtherapiesforparkinsonsdiseaseinaustralia‏ ‎‡A Practical approaches to commencing device-assisted therapies for Parkinson's disease in Australia.‏ ‎‡9 1‏
919 ‎‡a progressiveparkinsonismoculomotorabnormalitiesandautonomicdysfunctionclinicopathologicalcase‏ ‎‡A Progressive parkinsonism, oculomotor abnormalities and autonomic dysfunction: clinicopathological case.‏ ‎‡9 1‏
919 ‎‡a pundinganddyskinesias‏ ‎‡A Punding and dyskinesias‏ ‎‡9 1‏
919 ‎‡a pundinginparkinsonsdisease‏ ‎‡A Punding in Parkinson's disease‏ ‎‡9 1‏
919 ‎‡a pundinginparkinsonsdiseaseitsrelationtothedopaminedysregulationsyndrome‏ ‎‡A Punding in Parkinson's disease: its relation to the dopamine dysregulation syndrome‏ ‎‡9 1‏
919 ‎‡a quantifyingtheimpactofdyskinesiasinpdthepdys26apatientbasedoutcomemeasure‏ ‎‡A Quantifying the impact of dyskinesias in PD: the PDYS-26: a patient-based outcome measure‏ ‎‡9 1‏
919 ‎‡a recklessgenerosityinparkinsonsdisease‏ ‎‡A Reckless generosity in Parkinson's disease‏ ‎‡9 1‏
919 ‎‡a recognitionofadopaminereplacementtherapydependencesyndromeinparkinsonsdiseaseapilotstudy‏ ‎‡A Recognition of a dopamine replacement therapy dependence syndrome in Parkinson's disease: a pilot study‏ ‎‡9 1‏
919 ‎‡a scalestoassessimpulsiveandcompulsivebehaviorsinparkinsonsdiseasecritiqueandrecommendations‏ ‎‡A Scales to assess impulsive and compulsive behaviors in Parkinson's disease: Critique and recommendations‏ ‎‡9 1‏
919 ‎‡a sleepdisturbanceandimpulsivecompulsivebehavioursinparkinsonsdisease‏ ‎‡A Sleep disturbance and impulsive-compulsive behaviours in Parkinson's disease‏ ‎‡9 1‏
919 ‎‡a sodiumselenateasadiseasemodifyingtreatmentforprogressivesupranuclearpalsyprotocolforaphase2randomiseddoubleblindplacebocontrolledtrial‏ ‎‡A Sodium selenate as a disease-modifying treatment for progressive supranuclear palsy: protocol for a phase 2, randomised, double-blind, placebo-controlled trial‏ ‎‡9 1‏
919 ‎‡a subjectiveperceptionofsleepbenefitinparkinsonsdiseasevalidorirrelevant‏ ‎‡A Subjective perception of sleep benefit in Parkinson's disease: Valid or irrelevant?‏ ‎‡9 1‏
919 ‎‡a 14yearfinalreportoftherandomizedpdrguktrialcomparing3initialtreatmentsinpd‏ ‎‡A Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD.‏ ‎‡9 1‏
919 ‎‡a feasibilityofsmartphonebasedtestingofinterferenceinparkinsonsdisease‏ ‎‡A Feasibility of Smartphone-Based Testing of Interference in Parkinson’s Disease‏ ‎‡9 1‏
919 ‎‡a expertconsensusgroupreportontheuseofapomorphineinthetreatmentofparkinsonsdiseaseclinicalpracticerecommendations‏ ‎‡A Expert Consensus Group report on the use of apomorphine in the treatment of Parkinson's disease--Clinical practice recommendations‏ ‎‡9 1‏
919 ‎‡a excessivehoardinginparkinsonsdisease‏ ‎‡A Excessive hoarding in Parkinson's disease‏ ‎‡9 1‏
919 ‎‡a evaluationofnonmotorsymptomsindiagnosisofparkinsonismandtremor‏ ‎‡A Evaluation of Nonmotor Symptoms in Diagnosis of Parkinsonism and Tremor‏ ‎‡9 1‏
919 ‎‡a establishingapomorphinetreatmentinthailandunderstandingthechallengesandopportunitiesofparkinsonsdiseasemanagementindevelopingcountries‏ ‎‡A Establishing apomorphine treatment in Thailand: Understanding the challenges and opportunities of Parkinson's disease management in developing countries‏ ‎‡9 1‏
919 ‎‡a dyskineticpatientsshowreboundworseningofaffectafteranacute50dopachallenge‏ ‎‡A Dyskinetic patients show rebound worsening of affect after an acute L-dopa challenge.‏ ‎‡9 1‏
919 ‎‡a efficacyofapomorphineanonmotorperspective‏ ‎‡A The efficacy of apomorphine - A non-motor perspective‏ ‎‡9 1‏
919 ‎‡a useofacolorcodedprobabilityscaletointerpretsmelltestsinsuspectedparkinsonism‏ ‎‡A The use of a color coded probability scale to interpret smell tests in suspected parkinsonism‏ ‎‡9 1‏
919 ‎‡a dopaminedysregulationsyndromeinparkinsonsdisease‏ ‎‡A Dopamine dysregulation syndrome in Parkinson's disease‏ ‎‡9 1‏
919 ‎‡a treatmentadvancesinparkinsondiseasesamescriptdifferentcast‏ ‎‡A Treatment advances in Parkinson disease: Same script different cast?‏ ‎‡9 1‏
919 ‎‡a validationofasmartphoneapplicationmeasuringmotorfunctioninparkinsonsdisease‏ ‎‡A Validation of a Smartphone Application Measuring Motor Function in Parkinson's Disease‏ ‎‡9 1‏
919 ‎‡a vasogenicoedemawithnomasslesion‏ ‎‡A Vasogenic oedema with no mass lesion‏ ‎‡9 1‏
919 ‎‡a dopaminedysregulationsyndromeimpulsecontroldisordersandpundingafterdeepbrainstimulationsurgeryforparkinsonsdisease‏ ‎‡A Dopamine dysregulation syndrome, impulse control disorders and punding after deep brain stimulation surgery for Parkinson's disease‏ ‎‡9 1‏
919 ‎‡a dopaminedysregulationsyndromeanoverviewofitsepidemiologymechanismsandmanagement‏ ‎‡A Dopamine dysregulation syndrome: an overview of its epidemiology, mechanisms and management‏ ‎‡9 1‏
919 ‎‡a dodyskinesiaandpainsharecommonpathophysiologicalmechanismsinparkinsonsdisease‏ ‎‡A Do dyskinesia and pain share common pathophysiological mechanisms in Parkinson's disease?‏ ‎‡9 1‏
919 ‎‡a cueinducedstriataldopaminereleaseinparkinsonsdiseaseassociatedimpulsivecompulsivebehaviours‏ ‎‡A Cue-induced striatal dopamine release in Parkinson's disease-associated impulsive-compulsive behaviours.‏ ‎‡9 1‏
919 ‎‡a continuoussubcutaneousapomorphinetherapyimprovesdyskinesiasinparkinsonsdiseaseaprospectivestudyusingsingledosechallenges‏ ‎‡A Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges‏ ‎‡9 1‏
919 ‎‡a compulsiveuseofdopaminergicdrugtherapyinparkinsonsdiseaserewardandantireward‏ ‎‡A Compulsive use of dopaminergic drug therapy in Parkinson's disease: reward and anti-reward‏ ‎‡9 1‏
919 ‎‡a compulsiveuseofdopaminereplacementtherapyinparkinsonsdiseaserewardsystemsgoneawry‏ ‎‡A Compulsive use of dopamine replacement therapy in Parkinson's disease: reward systems gone awry?‏ ‎‡9 1‏
919 ‎‡a compulsivedruguselinkedtosensitizedventralstriataldopaminetransmission‏ ‎‡A Compulsive drug use linked to sensitized ventral striatal dopamine transmission‏ ‎‡9 1‏
919 ‎‡a clinicalspectrumofimpulsecontroldisordersinparkinsonsdisease‏ ‎‡A Clinical spectrum of impulse control disorders in Parkinson's disease‏ ‎‡9 1‏
919 ‎‡a briefpsychiatricscreeningquestionnaireinparkinsonsdisease‏ ‎‡A Brief Psychiatric Screening Questionnaire in Parkinson's Disease‏ ‎‡9 1‏
919 ‎‡a automatedassessmentofbradykinesiaanddyskinesiainparkinsonsdisease‏ ‎‡A Automated assessment of bradykinesia and dyskinesia in Parkinson's disease.‏ ‎‡9 1‏
919 ‎‡a youngwomanwithslowlyprogressivegeneralizeddystonia‏ ‎‡A A young woman with slowly-progressive generalized dystonia‏ ‎‡9 1‏
919 ‎‡a fpcitspectstudyinvascularparkinsonismandparkinsonsdisease‏ ‎‡A [123I] FP-CIT spect study in vascular parkinsonism and Parkinson's disease‏ ‎‡9 1‏
919 ‎‡a impulsecontrolandrelateddisordersinparkinsonsdiseasereview‏ ‎‡A Impulse control and related disorders in Parkinson's disease: review‏ ‎‡9 1‏
919 ‎‡a impulsiveandcompulsivebehaviorsinparkinsonsdisease‏ ‎‡A Impulsive and compulsive behaviors in Parkinson's disease.‏ ‎‡9 1‏
919 ‎‡a impulsivecompulsivespectrumbehaviorsinpathologicallyconfirmedprogressivesupranuclearpalsy‏ ‎‡A Impulsive-compulsive spectrum behaviors in pathologically confirmed progressive supranuclear palsy‏ ‎‡9 1‏
919 ‎‡a integratingpatientconcernsintoparkinsonsdiseasemanagement‏ ‎‡A Integrating Patient Concerns into Parkinson's Disease Management‏ ‎‡9 1‏
919 ‎‡a ispundingastereotypy‏ ‎‡A Is punding a stereotypy?‏ ‎‡9 1‏
919 ‎‡a doparesponsiveparkinsonssyndromeinassociationwithphenylketonuriainvivodopaminetransporterandd2receptorfindings‏ ‎‡A L-Dopa-responsive Parkinson's syndrome in association with phenylketonuria: In vivo dopamine transporter and D2 receptor findings‏ ‎‡9 1‏
919 ‎‡a managementofadvancedtherapiesinparkinsonsdiseasepatientsintimesofhumanitariancrisisthecovid19experience‏ ‎‡A Management of Advanced Therapies in Parkinson's Disease Patients in Times of Humanitarian Crisis: The COVID-19 Experience‏ ‎‡9 1‏
919 ‎‡a motorinhibitioninpatientswithgillesdelatourettesyndromefunctionalactivationpatternsasrevealedbyeegcoherence‏ ‎‡A Motor inhibition in patients with Gilles de la Tourette syndrome: functional activation patterns as revealed by EEG coherence.‏ ‎‡9 1‏
919 ‎‡a mucunapruriensinparkinsonsdiseaseadoubleblindclinicalandpharmacologicalstudy‏ ‎‡A Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study‏ ‎‡9 1‏
919 ‎‡a neuronalintranuclearinclusiondiseasereportonacaseoriginallydiagnosedasdoparesponsivedystoniawithlewybodies‏ ‎‡A Neuronal intranuclear inclusion disease: report on a case originally diagnosed as dopa-responsive dystonia with Lewy bodies‏ ‎‡9 1‏
919 ‎‡a objectivemeasurementandcharacterizationofsleepbenefitinparkinsonsdisease‏ ‎‡A Objective Measurement and Characterization of Sleep Benefit in Parkinson's Disease‏ ‎‡9 1‏
919 ‎‡a painanddyskinesiainparkinsonsdiseasemaysharecommonpathophysiologicalmechanismsanfmristudy‏ ‎‡A Pain and dyskinesia in Parkinson's disease may share common pathophysiological mechanisms - An fMRI study‏ ‎‡9 1‏
919 ‎‡a painsensitivityinparkinsonsdiseasesystematicreviewandmetaanalysis‏ ‎‡A Pain sensitivity in Parkinson's disease: Systematic review and meta-analysis‏ ‎‡9 1‏
919 ‎‡a parkinsondiseaseasystemicreviewofpainsensitivitiesanditsassociationwithclinicalpainandresponsetodopaminergicstimulation‏ ‎‡A Parkinson disease: A systemic review of pain sensitivities and its association with clinical pain and response to dopaminergic stimulation‏ ‎‡9 1‏
919 ‎‡a parkinsonismduetokernohannotchclinicalstructuralandfunctionalimagingcorrelates‏ ‎‡A Parkinsonism due to Kernohan notch: clinical, structural, and functional imaging correlates.‏ ‎‡9 1‏
946 ‎‡a b‏ ‎‡9 1‏
996 ‎‡2 CAOONL|ncf11546072‏
996 ‎‡2 BNF|17073379‏
996 ‎‡2 LC|nb2010025473‏
996 ‎‡2 LC|no2016162496‏
996 ‎‡2 ISNI|000000011560872X‏
996 ‎‡2 CAOONL|ncf10317659‏
996 ‎‡2 BIBSYS|90512318‏
996 ‎‡2 LC|nb 97077862‏
996 ‎‡2 BIBSYS|90673877‏
996 ‎‡2 SUDOC|227488717‏
996 ‎‡2 LC|nb2002053460‏
996 ‎‡2 LC|no2008186039‏
996 ‎‡2 NKC|pna2005307306‏
996 ‎‡2 PLWABN|9810608868705606‏
996 ‎‡2 ISNI|0000000121464048‏
996 ‎‡2 NTA|073236063‏
996 ‎‡2 ISNI|0000000109750164‏
996 ‎‡2 BIBSYS|2091464‏
996 ‎‡2 LC|no2016054709‏
996 ‎‡2 SUDOC|235453773‏
996 ‎‡2 BIBSYS|90964666‏
996 ‎‡2 LC|n 2018182946‏
996 ‎‡2 ISNI|0000000041309830‏
996 ‎‡2 LC|no2002074165‏
996 ‎‡2 ISNI|0000000038768825‏
996 ‎‡2 SUDOC|193837137‏
996 ‎‡2 LC|nb 99131890‏
996 ‎‡2 LC|nb2008019731‏
996 ‎‡2 BIBSYS|11002174‏
996 ‎‡2 LC|no2006000537‏
996 ‎‡2 SUDOC|131201204‏
996 ‎‡2 PLWABN|9810691063805606‏
996 ‎‡2 ISNI|0000000048767658‏
996 ‎‡2 LC|n 87813224‏
996 ‎‡2 ISNI|0000000440055591‏
996 ‎‡2 ISNI|0000000069385261‏
996 ‎‡2 CAOONL|ncf10306698‏
996 ‎‡2 SUDOC|079945228‏
996 ‎‡2 ISNI|0000000029395318‏
996 ‎‡2 ISNI|0000000015531403‏
996 ‎‡2 LC|nb2017014984‏
996 ‎‡2 DNB|1279649178‏
996 ‎‡2 LC|n 82208850‏
996 ‎‡2 ISNI|0000000046826714‏
996 ‎‡2 ISNI|0000000028192834‏
996 ‎‡2 SUDOC|087098695‏
996 ‎‡2 LC|n 2002096223‏
996 ‎‡2 LC|no 99073250‏
996 ‎‡2 SUDOC|035663952‏
996 ‎‡2 NDL|00439055‏
996 ‎‡2 LC|n 00007234‏
996 ‎‡2 BIBSYS|4086814‏
996 ‎‡2 ISNI|0000000077338393‏
996 ‎‡2 NUKAT|n 2021126346‏
996 ‎‡2 CAOONL|ncf10320341‏
996 ‎‡2 LC|n 93008575‏
996 ‎‡2 BIBSYS|90830170‏
996 ‎‡2 PLWABN|9812831479105606‏
996 ‎‡2 LC|n 90692493‏
996 ‎‡2 ISNI|0000000115708464‏
996 ‎‡2 LC|no2009140259‏
996 ‎‡2 LC|no2015004269‏
996 ‎‡2 LC|no2018062396‏
996 ‎‡2 RERO|A011017272‏
996 ‎‡2 NUKAT|n 96003112‏
996 ‎‡2 BIBSYS|90201148‏
996 ‎‡2 DNB|139496211‏
996 ‎‡2 DNB|1213058651‏
996 ‎‡2 LC|nb2010025487‏
996 ‎‡2 LC|no2005000512‏
996 ‎‡2 ISNI|0000000109874941‏
996 ‎‡2 BIBSYS|14064232‏
996 ‎‡2 DNB|112324667X‏
996 ‎‡2 PLWABN|9811265329005606‏
996 ‎‡2 LC|n 2015016119‏
996 ‎‡2 ISNI|0000000367553075‏
996 ‎‡2 NUKAT|n 2011043157‏
996 ‎‡2 SUDOC|194871711‏
996 ‎‡2 NTA|071607838‏
996 ‎‡2 ISNI|0000000039454086‏
996 ‎‡2 BIBSYS|90735281‏
996 ‎‡2 NUKAT|n 2006147334‏
996 ‎‡2 NSK|000637262‏
996 ‎‡2 J9U|987007333216105171‏
996 ‎‡2 NII|DA14169247‏
996 ‎‡2 BIBSYS|1009305‏
996 ‎‡2 ISNI|0000000023137772‏
996 ‎‡2 DNB|1158098790‏
996 ‎‡2 NUKAT|n 2016080603‏
996 ‎‡2 LC|nb2008019718‏
996 ‎‡2 BNF|13486702‏
996 ‎‡2 J9U|987007323889405171‏
996 ‎‡2 ISNI|0000000071160723‏
996 ‎‡2 BNF|16507865‏
996 ‎‡2 ISNI|0000000052370004‏
996 ‎‡2 BIBSYS|1707990460511‏
996 ‎‡2 ISNI|0000000054296397‏
996 ‎‡2 ISNI|0000000433536418‏
996 ‎‡2 NUKAT|n 2005090377‏
996 ‎‡2 LC|n 92033025‏
996 ‎‡2 J9U|987007325593405171‏
996 ‎‡2 KRNLK|KAC2020N3809‏
996 ‎‡2 BNF|16189984‏
996 ‎‡2 B2Q|0000103068‏
996 ‎‡2 PLWABN|9810557333205606‏
996 ‎‡2 NTA|130251062‏
996 ‎‡2 LC|nr 95002213‏
996 ‎‡2 J9U|987007430108005171‏
996 ‎‡2 LC|n 00113507‏
996 ‎‡2 BIBSYS|4023113‏
996 ‎‡2 J9U|987007362287105171‏
996 ‎‡2 LC|n 96058452‏
996 ‎‡2 BIBSYS|3013468‏
996 ‎‡2 BIBSYS|90913822‏
996 ‎‡2 LC|n 78001223‏
996 ‎‡2 DNB|122329252‏
996 ‎‡2 ISNI|0000000028261676‏
996 ‎‡2 RERO|A012952390‏
996 ‎‡2 ISNI|0000000027351223‏
996 ‎‡2 PTBNP|85836‏
996 ‎‡2 LC|n 78024153‏
996 ‎‡2 ISNI|0000000077405891‏
996 ‎‡2 LC|n 87117810‏
996 ‎‡2 LC|nr 93023142‏
996 ‎‡2 ISNI|0000000401987919‏
996 ‎‡2 BIBSYS|11049533‏
996 ‎‡2 NKC|xx0141414‏
996 ‎‡2 NTA|213017423‏
996 ‎‡2 ISNI|0000000451394150‏
996 ‎‡2 LIH|LNB:V-159903;=BN‏
996 ‎‡2 ISNI|000000005160813X‏
996 ‎‡2 LC|n 2009160924‏
996 ‎‡2 NUKAT|n 2013177117‏
996 ‎‡2 KRNLK|KAC202308461‏
996 ‎‡2 NTA|070713502‏
996 ‎‡2 LC|no2005023069‏
996 ‎‡2 LC|no2015005425‏
996 ‎‡2 PLWABN|9810680474705606‏
996 ‎‡2 NUKAT|n 2007022615‏
996 ‎‡2 NUKAT|n 2016046256‏
996 ‎‡2 J9U|987007378698205171‏
996 ‎‡2 N6I|vtls001393190‏
996 ‎‡2 DNB|128110139‏
996 ‎‡2 PLWABN|9810651074405606‏
996 ‎‡2 PLWABN|9810697561305606‏
996 ‎‡2 SUDOC|149549393‏
996 ‎‡2 NUKAT|n 2011080141‏
996 ‎‡2 ISNI|000000004055632X‏
996 ‎‡2 ISNI|0000000076689300‏
996 ‎‡2 BIBSYS|8018177‏
996 ‎‡2 LC|no2008111689‏
996 ‎‡2 NTA|339264195‏
996 ‎‡2 BIBSYS|4103980‏
996 ‎‡2 NTA|08490271X‏
996 ‎‡2 LC|no2018156590‏
996 ‎‡2 LC|nb2008019739‏
996 ‎‡2 NUKAT|n 2009048676‏
996 ‎‡2 PTBNP|1059083‏
996 ‎‡2 CAOONL|ncf10012208‏
996 ‎‡2 ISNI|0000000116595502‏
996 ‎‡2 ISNI|0000000083276977‏
996 ‎‡2 J9U|987007334688505171‏
996 ‎‡2 LC|nb2008019733‏
996 ‎‡2 LC|n 92026381‏
996 ‎‡2 LC|no2018094506‏
996 ‎‡2 NUKAT|n 98040723‏
996 ‎‡2 SUDOC|230534430‏
996 ‎‡2 ISNI|0000000032906393‏
996 ‎‡2 J9U|987007317791905171‏
996 ‎‡2 LC|n 88277477‏
996 ‎‡2 SUDOC|260880752‏
996 ‎‡2 J9U|987007340826205171‏
996 ‎‡2 ISNI|0000000033016448‏
996 ‎‡2 NUKAT|n 2013075384‏
996 ‎‡2 LC|nb2007019796‏
996 ‎‡2 BIBSYS|90181035‏
996 ‎‡2 LC|n 90641617‏
996 ‎‡2 LC|n 2014190074‏
996 ‎‡2 BIBSYS|90218712‏
996 ‎‡2 BIBSYS|90117289‏
996 ‎‡2 DNB|138594171‏
996 ‎‡2 RERO|A003225889‏
996 ‎‡2 J9U|987007345181805171‏
996 ‎‡2 ISNI|0000000067641241‏
996 ‎‡2 BIBSYS|90576820‏
996 ‎‡2 BNF|16753852‏
996 ‎‡2 ISNI|0000000416660003‏
996 ‎‡2 LC|no2015096186‏
996 ‎‡2 ISNI|0000000067492557‏
996 ‎‡2 SUDOC|242790321‏
996 ‎‡2 BIBSYS|90172328‏
996 ‎‡2 LC|n 88295991‏
996 ‎‡2 SUDOC|146643429‏
996 ‎‡2 SUDOC|12817109X‏
996 ‎‡2 SUDOC|06015246X‏
996 ‎‡2 NTA|114140413‏
996 ‎‡2 LC|n 85368174‏
996 ‎‡2 J9U|987007335499005171‏
996 ‎‡2 LC|n 89651661‏
996 ‎‡2 BIBSYS|4103761‏
996 ‎‡2 PLWABN|9810557199905606‏
996 ‎‡2 DNB|1210878836‏
996 ‎‡2 DNB|142728462‏
996 ‎‡2 NKC|ctu2015859030‏
996 ‎‡2 LC|n 94020060‏
996 ‎‡2 ISNI|0000000024226144‏
996 ‎‡2 NII|DA01069614‏
996 ‎‡2 RERO|A003225890‏
996 ‎‡2 SUDOC|243796900‏
996 ‎‡2 BIBSYS|90405549‏
996 ‎‡2 ISNI|0000000394506098‏
996 ‎‡2 LC|n 2004001570‏
996 ‎‡2 LC|n 2012182760‏
996 ‎‡2 LC|no2017112666‏
996 ‎‡2 ISNI|0000000389075967‏
996 ‎‡2 NTA|073048658‏
996 ‎‡2 LC|nb2015019570‏
996 ‎‡2 LIH|LNB:C_s__k_M;=B__‏
996 ‎‡2 LC|no2019174103‏
996 ‎‡2 BNE|XX1030522‏
996 ‎‡2 LC|nr 92023386‏
996 ‎‡2 LC|n 2014066883‏
996 ‎‡2 RERO|A003225818‏
996 ‎‡2 RERO|A003225819‏
996 ‎‡2 CAOONL|ncf11293622‏
996 ‎‡2 ISNI|0000000117314397‏
996 ‎‡2 DNB|130872261‏
996 ‎‡2 DNB|171113314‏
996 ‎‡2 NII|DA06541681‏
996 ‎‡2 DNB|1057701653‏
996 ‎‡2 NII|DA00369317‏
996 ‎‡2 LNB|LNC10-000010187‏
996 ‎‡2 SUDOC|265057620‏
996 ‎‡2 RERO|A003225816‏
996 ‎‡2 LNB|LNC10-000063524‏
996 ‎‡2 ISNI|0000000038925499‏
996 ‎‡2 DNB|142586560‏
996 ‎‡2 J9U|987007345242205171‏
996 ‎‡2 LC|n 2008086097‏
996 ‎‡2 ISNI|0000000391713016‏
996 ‎‡2 NUKAT|n 2012167044‏
996 ‎‡2 PLWABN|9810633239905606‏
996 ‎‡2 LC|no2006103311‏
996 ‎‡2 NTA|306681080‏
996 ‎‡2 RERO|A016522277‏
996 ‎‡2 ISNI|0000000445325482‏
996 ‎‡2 ISNI|0000000497836743‏
996 ‎‡2 BNC|981058526401606706‏
996 ‎‡2 NTA|306211394‏
996 ‎‡2 ISNI|0000000042023586‏
997 ‎‡a 0 0 lived 0 0‏ ‎‡9 1‏